The European chemical margin crisis
European chemical manufacturers face an unprecedented margin crisis. After years of aggressive cost reduction, driven by energy prices four times higher than US competitors, production optimisation has reached its limit. Costs have been cut to the bone, capacity sits at 75%, and further efficiency is nearly impossible.
The numbers are sobering. While the global chemical industry reached $6.18 trillion in 2024, European manufacturers are fighting what industry leaders call a severe recession. In Germany, Europe’s chemical powerhouse, a 2% rise in production came with a 2% fall in sales to €221 billion, and products were on average 2.5% cheaper than the year before. Production across the European chemical and pharmaceutical industry remains 17% below 2018 levels.
Capacity utilisation versus the profitability threshold. Energy costs remain roughly four times US levels. Sources: industry reporting, 2024.
You cannot run plants at 75% and cut further. You cannot eliminate more staff without compromising operations. You cannot reduce energy use beyond physical limits. When manufacturing costs reach their floor, only one margin lever remains: commercial execution. The ability to sell value rather than specifications, and to justify premium pricing through demonstrated cost-in-use.
Three simultaneous crises
Most European chemical sales teams are structurally unprepared for this. They face three crises at once.
Brain drain. A generation of chemists, engineers and application scientists is retiring, taking irreplaceable application knowledge. These are the people who could articulate exactly why a customer should pay more, and quantify the savings. When they leave, the knowledge vanishes.
Commodity mindset. For decades, commodity pricing tracked published indexes, and buyers grew comfortable with transparent, market-based pricing. That conditioning now infects specialty sales: even selling differentiated products, teams default to commodity-style price discussions because they lack frameworks to quantify value.
Technical complexity. Chemical sales spans thousands of product variations, where small changes carry large cost implications. Understanding that requires deep knowledge most salespeople do not have. The result: sales cycles stretching 12 to 18 months, discounts of 15 to 25%, and margins compressing even as product costs stabilise.
McKinsey research puts purchasing at 20 to 60% of revenue for specialty players. A purchasing improvement of just 6 to 10% can add 3 to 5 points of EBIT. Squeezed on both energy cost and price, even modest gains in commercial execution become survival imperatives.
Insight 1: your best technical experts are your worst commercial liability
Picture the pattern. A customer needs a specialty coating to cut their defect rate. Your salesperson gathers basic information and promises to “get back to them”, then finds Klaus, the 62-year-old application chemist of 35 years, who identifies the right formulation and joins the call. The deal moves forward. Everyone is happy. Until Klaus retires next year, and the next similar opportunity arrives with nobody able to evaluate it.
Technical experts become the bottleneck in the sales process. They never set out to create the dependency; they were doing their jobs. But the organisation’s ability to sell specialty products ends up resting on a handful of people who are late in their careers, already overloaded, and impossible to clone. When they retire, most companies quietly retreat toward simpler, commoditised products and compete on price. Margins compress further.
The goal is not to make salespeople as knowledgeable as your experts. It is to capture expert knowledge and convert it into frameworks salespeople can use.
When Klaus evaluates an opportunity, he is not recalculating chemistry from first principles. He is pattern-matching against decades of experience: this application is like that one, these variables matter, those do not. Those patterns can be documented, systematised and taught. At one specialty chemical company, every complex application used to require one of three senior scientists and cycles averaged 14 months. After their knowledge was captured into sales-facing frameworks, average salespeople could qualify, recommend and articulate value independently, and cycles dropped to 9 months. The frameworks did not make salespeople into chemists. They made salespeople effective at selling chemistry.
In practice that means application qualification decision trees, value quantification models that calculate cost-in-use, technical positioning guides written in outcome language, vetted objection responses, and a searchable reference-application database. Teams become self-sufficient on 70 to 80% of opportunities, escalating only the genuinely novel. The experts become more valuable, not less, freed to work on innovation.
Insight 2: commodity pricing has infected your specialty sales process
Customer: “What’s your price on this specialty additive?”
Salesperson: “€12 per kilogram.”
Customer: “Your competitor quoted €10.50.”
Salesperson: “Let me see what I can do.”
Five minutes later the salesperson is asking their manager to approve €10.50 to “stay competitive”. Everyone thinks this is successful selling. It is not. It is commodity trading dressed up as specialty sales.
European chemical manufacturers offer average discounts of 15 to 25% off list, based not on value delivered but on buyer pressure and an inability to defend price. The cost is staggering: for a €500 million specialty company, moving price realisation five points, from 20% discounting to 15%, delivers €25 million straight to the bottom line, more than most operational programmes achieve.
The problem intensifies because buyers have grown sophisticated while sellers have not. A skilled procurement professional reduces the decision to “do you meet spec, at what price”, neutralising your technical advantages. Most salespeople lack the framework to redirect: “Yes, we meet spec, and here is why customers in your application typically see 15 to 20% lower total costs despite our higher unit price.” Specialty chemicals rarely compete on unit price. They compete on cost-in-use.
One European manufacturer sold a high-performance lubricant additive at €18 per kilogram against competitors at €12, and kept losing on price despite superior performance. Working with their application scientists, they built a value quantification framework for the most common application, automotive transmission fluids: diagnostic questions about drain intervals, warranty claims and field failures, plus a simple tool calculating total cost of ownership. Salespeople could then show the €18 additive delivered €0.45 per vehicle in savings, compelling for a manufacturer building hundreds of thousands of vehicles.
Win rate on qualified opportunities. Average selling price rose 8% and sales cycles shortened 30%. Source: Klozers client implementation.
The framework did not require salespeople to become tribologists. It required them to follow a diagnostic process, input customer data, and present results confidently. One specialty polymer manufacturer cut average discounting from 22% to 12% over 18 months, worth €45 million a year. A coatings producer lifted win rates from 40% to 61% while holding premium pricing. None of this came from hiring more chemists. It came from frameworks that let salespeople have value conversations they could not have before.
Insight 3: long sales cycles are a value articulation problem
The complaint is universal: “Procurement drags everything out, customers take 12 to 18 months.” Sales directors blame procurement, consensus decisions, risk-averse technical teams, everything except the real cause. Every day a cycle extends beyond what is technically necessary is a failure of value articulation.
Compare two paths. In the first, the salesperson presents specifications, the customer runs trials that eventually happen, results are positive but unquantified, alternatives get evaluated, procurement drags on, and perhaps it closes at 16 months. In the second, the salesperson diagnoses current costs on the first call, presents a cost-in-use analysis showing €200,000 of annual savings, proposes a structured trial with clear success metrics that runs in six weeks, and closes in seven months because the economic case was clear throughout.
Clarity accelerates decisions. Ambiguity extends them.
Procurement is not deliberately slowing you down; it is minimising risk. A request that says “this additive reduces waste 8%, saving €180,000 for €120,000” moves quickly. One that says “engineering wants this and it costs 30% more” should be delayed. Much of the 12 to 18 months is technical evaluation run informally: “send some samples”, months pass, an unspecified problem occurs, different samples, more months. Replace that with structured validation, agreed success criteria, protocol, timeline, decision criteria and owners, and evaluation happens in weeks. The difference is not the chemistry. It is the commercial framework around it.
Average specialty sales cycle. A 35% reduction lets teams close more deals per year with the same headcount. Source: Klozers client implementation.
Treat procurement as a partner, not an adversary. A buyer who can take a well-documented value case to management looks good, and negotiations then focus on terms, not on whether the purchase is justified at all. Long cycles are a symptom. The disease is unclear value articulation.
The solution: systematic value-based selling
The three insights point to one theme: chemical manufacturers need frameworks that let salespeople sell value without deep technical expertise. Five build on each other.
- Expert knowledge capture. Before experts retire, document which applications are most profitable, the value drivers your products address, the diagnostic questions that qualify a fit, and vetted objection responses. Led by commercial teams, not R&D, the aim is commercial intelligence, not technical documentation.
- Value discovery. Diagnostic question sets that uncover the customer’s current costs and problems, even when the salesperson does not fully grasp the technical causes.
- Value quantification. Pre-built TCO calculators and ROI templates that turn simple customer inputs into a total-cost comparison, so salespeople present the economic case confidently.
- Value communication. Templates and executive one-pagers that tell the cost-in-use story in the language of financial decision-makers, plus structured technical validation protocols.
- Progressive qualification. Clear stage definitions, deal-health indicators and disqualification criteria, so salespeople invest time in deals that can actually close.
Implementation principles matter as much as the frameworks: build from the inside out rather than importing generic methodology; keep frameworks technically accurate but in sales-facing language; provide real tools, not training alone; enable managers before salespeople; and start with the highest-margin applications to prove ROI, then expand.
The margin recovery equation
Value-based selling compounds through several channels: better price realisation (five points of reduced discounting flows straight to margin), a mix shift toward specialty, shorter cycles that let teams close around 35% more deals with the same resources, higher win rates on qualified opportunities, and stickier customer retention. Cumulatively these can deliver 8 to 12 points of EBIT margin improvement, far more than further cost-cutting, achieved through commercial execution.
This is how we work with chemical teams.
A 90-day roadmap
Weeks 1 to 3, foundation and assessment. Secure commercial sponsorship, baseline current discounting, cycle length and win rates, identify the experts whose knowledge is most at risk, and select three to five high-value applications.
Weeks 4 to 8, framework development. Build the discovery question sets, TCO calculators and communication templates for those applications, validated by experts, then enable managers first and certify them before any team rollout.
Weeks 9 to 12, rollout and reinforcement. Train salespeople on live opportunities, coach weekly against the frameworks, refine the tools from field use, and update CRM to capture value-selling activity. Expect a short dip in weeks four to six as people learn, with competence building by weeks eight to twelve. Full ROI typically lands in 9 to 12 months, with 5 to 10 points of margin improvement where execution is rigorous.
Conclusion
Manufacturing costs have reached their floor. Energy remains four times US levels, capacity sits at 75%, and further cost reduction is not a path to recovery. The only remaining lever is commercial execution. The companies that thrive will capture expert knowledge before it retires, equip teams with frameworks that enable value articulation without PhD-level expertise, and compress cycles by creating clarity from the first conversation. This is not optional. It is the difference between margin recovery and continued decline.
Five questions decide it: can your team articulate cost-in-use confidently today; if not, how much margin are you leaving on the table; what happens when your senior application chemists retire; do you have frameworks to capture their knowledge before they go; and how long can you sustain 12 to 18 month cycles while competitors move faster?
About Klozers. Klozers is a UK-based B2B sales training and coaching company serving technical and manufacturing companies, with a “build from the inside out” method that captures what already works in a client’s organisation rather than imposing external frameworks. For chemical manufacturers we capture expert knowledge, build value-based selling frameworks and TCO tools, enable managers first, and run 90-day transformation programmes tied to measurable margin recovery. sa***@*****rs.com · +44 (0) 3000 230513 · klozers.com
